You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

 

Online download statistics by month:

Online download statistics by month: October 2020 to August 2021

AbstractFullPdf
Oct 202012671267511
Nov 2020270270132
Dec 202013013058
Jan 202120420468
Feb 2021388388112
Mar 202121321394
Apr 202117917965
May 202114914970
Jun 202118318271
Jul 202110510544
Aug 202113813861
Total322632251286